EcoDrugPlus

Endothelial Pas Domain Protein 1b

Ensembl ID : ENSSMAG00000005228
Gene Symbol: EPAS1B
2 Cross references
210 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSSMAG00000001956
Gene Symbol: ECE1
1 Cross references
230 Possible Orthologues:

Endothelin Receptor Type A

Ensembl ID : ENSSMAG00000015856
Gene Symbol: EDNRA
3 Cross references
197 Possible Orthologues:

Endothelin Receptor Type Aa

Ensembl ID : ENSSMAG00000004502
Gene Symbol: EDNRAA
3 Cross references
205 Possible Orthologues:

Epidermal Growth Factor Receptor A (Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog, Avian)

Ensembl ID : ENSSMAG00000017876
Gene Symbol: EGFRA
3 Cross references
212 Possible Orthologues:

Epoxide Hydrolase 2, Cytoplasmic

Ensembl ID : ENSSMAG00000002936
Gene Symbol: EPHX2
2 Cross references
203 Possible Orthologues:

Equilibrative Nucleoside Transporter 1-Like

Ensembl ID : ENSSMAG00000017934
Gene Symbol: LOC118283633
2 Cross references
209 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSSMAG00000017557
Gene Symbol: ERBB2
3 Cross references
200 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3a

Ensembl ID : ENSSMAG00000001824
Gene Symbol: ERBB3A
2 Cross references
211 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3b

Ensembl ID : ENSSMAG00000002968
Gene Symbol: ERBB3B
1 Cross references
206 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSSMAG00000008828
Gene Symbol: ERBB4
3 Cross references
47 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4a

Ensembl ID : ENSSMAG00000010805
Gene Symbol: ERBB4A
1 Cross references
230 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).